Lipfendra significantly lowered LDL (“bad”) cholesterol in clinical trials, but experts say statins remain the first-line treatment for most patients.
- The FDA approved Lipfendra, the first oral PCSK9 inhibitor for adults with high cholesterol
- Clinical trials showed up to 59% reduction in LDL cholesterol with a safety profile comparable to placebo
- Lipfendra complements—not replaces—statins for people needing additional LDL lowering
The US Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), making it the first oral PCSK9 inhibitor for lowering low-density lipoprotein (LDL) or “bad” cholesterol in adults. Until now, medicines in this drug class were available only as injections (1✔ ✔Trusted Source
FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol
), (2✔ ✔Trusted Source
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
).
The once-daily tablet offers a new treatment option for adults with high cholesterol who need additional LDL reduction despite following diet, exercise, and standard cholesterol-lowering therapy.
The approval comes at a time when cardiovascular disease remains the leading cause of death globally, and high cholesterol continues to be a major modifiable risk factor.
According to the US FDA, Lipfendra demonstrated significant LDL reductions in Phase 3 clinical trials involving more than 3,200 participants while maintaining a safety profile comparable to placebo.
Advertisement
Why Has the FDA Approved Lipfendra for High Cholesterol?
Lipfendra has been approved as an adjunct to diet and exercise for adults with primary hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
Advertisement
Lipfendra at a Glance
|
Feature |
Details |
|
Brand name |
Lipfendra |
|
Generic name |
Enlicitide |
|
Drug class |
Oral PCSK9 inhibitor |
|
FDA approval |
July 2026 |
|
Approved by |
US Food and Drug Administration (FDA) |
|
Manufacturer |
Merck Sharp & Dohme LLC |
|
First-of-its-kind |
First oral PCSK9 inhibitor approved anywhere |
|
Indication |
Adults with primary hypercholesterolemia, including HeFH |
|
How it is used |
Along with diet, exercise and other cholesterol-lowering therapy |
|
Dosage form |
Once-daily oral tablet |
|
Review pathway |
FDA Priority Review |
Advertisement
How Does Lipfendra Lower Bad Cholesterol?
Low-density lipoprotein (LDL), commonly known as “bad cholesterol,” can gradually build up inside the walls of arteries. Over time, this buildup forms fatty plaques that narrow blood vessels, reducing blood flow and increasing the risk of heart attack and stroke.
Lipfendra works by targeting a protein called PCSK9, which plays an important role in controlling how much LDL cholesterol remains in the bloodstream. Normally, PCSK9 breaks down LDL receptors in the liver.
These receptors are responsible for removing LDL cholesterol from the blood. By blocking PCSK9, Lipfendra helps preserve more LDL receptors, allowing the liver to clear more LDL cholesterol and lower its levels in the body.
The process can be understood in the following steps.
|
Step |
What Happens? |
|
1. PCSK9 is active |
The PCSK9 protein binds to LDL receptors in the liver and causes them to break down. |
|
2. LDL receptors decrease |
With fewer LDL receptors available, the liver removes less LDL (“bad”) cholesterol from the bloodstream. |
|
3. LDL cholesterol builds up |
More LDL remains in the blood, where it can gradually accumulate inside artery walls and form plaques. |
|
4. Lipfendra blocks PCSK9 |
Lipfendra prevents PCSK9 from breaking down LDL receptors, helping preserve more of these receptors on liver cells. |
|
5. More LDL is removed |
The extra LDL receptors capture and remove more LDL cholesterol from the blood, leading to lower cholesterol levels. |
By offering the first oral way to block the PCSK9 protein, Lipfendra provides patients with a convenient alternative to injectable PCSK9 inhibitors while using the same cholesterol-lowering pathway.
How Effective Was Lipfendra in Clinical Trials?
Lipfendra’s approval was based on two Phase 3 randomized, double-blind, placebo-controlled clinical trials involving 3,207 adults who were already receiving maximally tolerated statin therapy.
The studies evaluated the medicine in adults with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk and in those with heterozygous familial hypercholesterolemia (HeFH).
Key findings from the trials included:
- 3,207 adults participated across the two Phase 3 studies.
- Participants continued maximally tolerated statin therapy, with or without other lipid-lowering medicines.
- Lipfendra reduced LDL (“bad”) cholesterol by 56% in adults with ASCVD or high cardiovascular risk.
- LDL cholesterol fell by 59% in adults with HeFH.
- The primary study goals were successfully achieved in both trials.
- Overall safety was comparable to placebo.
The FDA also reported that Lipfendra was generally well tolerated, with diarrhea and dizziness being the most commonly reported side effects.
While these findings demonstrate strong LDL-lowering benefits, researchers are continuing to evaluate whether Lipfendra also reduces the long-term risk of heart attacks, strokes, and cardiovascular deaths.
An ongoing cardiovascular outcomes trial is expected to provide further evidence on these clinical benefits.
Can Lipfendra Replace Statins?
The approval of Lipfendra has sparked interest in whether it could replace statins. According to a study published in the Journal of the American Heart Association (JAHA), the answer is no (3✔ ✔Trusted Source
Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment
).
While Lipfendra is a promising new option, statins remain the recommended first-line treatment, with Lipfendra mainly serving as an additional option for patients who need greater LDL cholesterol lowering or cannot tolerate statins.
Lipfendra vs Statins: Key Differences
|
Feature |
Lipfendra (Enlicitide) |
Statins |
|
Medicine type |
Oral PCSK9 inhibitor |
Cholesterol-lowering (statin) medicine |
|
How it works |
Helps the liver remove more LDL cholesterol |
Reduces cholesterol production in the liver |
|
LDL cholesterol lowering |
Faster reduction in the first month |
Slower initial reduction |
|
Long-term LDL control |
Similar to statins |
Similar to Lipfendra |
|
Heart attack and stroke protection |
Similar long-term outcomes in current evidence |
Strong long-term evidence available |
|
First-choice treatment |
No |
Yes |
|
Best suited for |
Patients needing extra LDL lowering or those who cannot tolerate statins |
Most people with high cholesterol |
The study found that PCSK9 inhibitors lowered LDL cholesterol more quickly during the first month, but long-term LDL reduction and cardiovascular outcomes were similar to statin therapy.
Researchers concluded that statins remain the cornerstone of cholesterol management, while Lipfendra offers an important additional treatment option for selected patients.
Why Could Lipfendra Be Important for India?
Although Lipfendra has been approved by the US FDA, it is not yet available in India. Before it can be prescribed, the medicine must receive approval from the Central Drugs Standard Control Organisation (CDSCO).
The need for newer cholesterol-lowering therapies is significant. According to an Indian Heart Journal review based on findings from the ICMR-INDIAB study, dyslipidemia is one of the leading contributors to India’s growing burden of coronary artery disease (4✔ ✔Trusted Source
Trends in epidemiology of dyslipidemias in India
Prevalence of Lipid Disorders in India
|
Lipid Disorder |
Estimated Prevalence |
|
Low HDL (“good”) cholesterol |
66.9% |
|
High triglycerides |
32.1% |
|
Hypercholesterolemia (high total cholesterol) |
24.0% |
|
High LDL (“bad”) cholesterol |
20.9% |
The review also found considerable differences in cholesterol abnormalities across states, highlighting the need for region-specific prevention and treatment strategies.
States with the Highest Reported Cholesterol Levels
|
Lipid Disorder |
States With Highest Prevalence |
|
High total cholesterol |
Kerala (50.3%), Goa (45.6%), Himachal Pradesh (39.6%) |
|
High LDL cholesterol |
Kerala (52.1%), Goa (46.8%), Rajasthan (34.8%) |
|
Low HDL cholesterol |
Reported across most Indian states |
|
High triglycerides |
Observed across several states with regional variation |
According to the researchers, India’s increasing burden of dyslipidemia is linked to changing lifestyles and a growing prevalence of obesity, diabetes, unhealthy diets, physical inactivity, and population aging.
The review recommends:
- Expanding routine cholesterol screening
- Increasing public awareness about lipid disorders
- Promoting early diagnosis and timely treatment
- Improving long-term adherence to cholesterol-lowering medicines
- Strengthening nationwide surveillance and research
While Lipfendra could eventually provide another treatment option for Indians who need additional LDL cholesterol lowering, healthy lifestyle habits, regular cholesterol testing, and statins will continue to remain the foundation of cardiovascular disease prevention, even as newer therapies become available.
Frequently Asked Questions
Q: What is Lipfendra?
A: Lipfendra (enlicitide) is the first FDA-approved oral PCSK9 inhibitor used to lower LDL (“bad”) cholesterol.
Q: How does Lipfendra lower bad cholesterol?
A: It blocks the PCSK9 protein, allowing the liver to remove more LDL cholesterol from the bloodstream.
Q: Who can take Lipfendra?
A: It is approved for adults with primary hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), alongside diet and exercise.
Q: Can Lipfendra replace statins?
A: No. Statins remain the first-choice treatment, while Lipfendra is an additional option for people needing greater LDL reduction or who cannot tolerate statins.
Q: How effective was Lipfendra in clinical trials?
A: It reduced LDL cholesterol by up to 56–59% in Phase 3 clinical trials involving more than 3,200 adults.
Q: What are the common side effects of Lipfendra?
A: The most commonly reported side effects were diarrhea and dizziness.
Q: Is Lipfendra available in India?
A: No. It has FDA approval in the US but still requires approval from India’s CDSCO before becoming available.
References:
- FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol – (https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-therapy-inhibits-proprotein-convertase-subtilisinkexin-type-9-pcsk9-lower?)
- FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol – (https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol?)
- Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment – (https://www.ahajournals.org/doi/10.1161/JAHA.125.047923)
- Trends in epidemiology of dyslipidemias in India – (https://www.sciencedirect.com/science/article/pii/S0019483223004571)
Source-Medindia